Liver function may change how cancer drug imlunestrant works

NCT ID NCT05440344

Completed Knowledge-focused Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed Phase 1 study looked at how imlunestrant, an oral drug, enters the bloodstream and leaves the body in women with and without liver impairment. 27 female participants took a single dose, and researchers measured drug levels over time. The goal is to understand if liver problems affect drug processing, which could guide future dosing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Imlunestrant (oral drug)
What this could lead to: If successful, this study could help doctors decide the right dose of imlunestrant for patients with liver problems.
What could go wrong: This is a very early, small study (27 people) focused on drug levels, not on treating any disease. Results may not predict real-world outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Hepatic Insufficiency liver failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY HEPATIC INSUFFICIENCY

Contacts and locations

Locations

American Research Corporation at Texas Liver Institute

San Antonio, Texas, 78215, United States
Inland Empire Liver Foundation

Rialto, California, 92377, United States
Orlando Clinical Research Center

Orlando, Florida, 32809, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.